Table 2.
Sensitivity and specificity analyses by pathology.
| Pathology | N | Specificity, % [95% CI] | Target values | |
|---|---|---|---|---|
| Specificity | Lower bound | |||
| Negative and non-APL | 292 | 80.8 [75.9–84.9] | 90% | 86% |
| Negative | 265 | 83.4 [78.4–87.4] | NA | NA |
| Pathology | N | Sensitivity, % [95% CI] | Target values | |
| Sensitivity | Lower bound | |||
| CRC | 30 | 73.3 [55.6–85.8] | 85% | 66% |
| CRC & HGD | 42 | 78.6 [64.1–88.3] | 76% | 60% |
| CRC & APL | 63 | 76.2 [64.4–85.0] | NA | NA |
| APL | 33 | 78.8 [62.2–89.3] | NA | NA |
| IBD-HGD | 11 | 100 [74.1–100] | NA | NA |
| IBD-LGD ≥ 1 cm | 13 | 84.6 [57.8–95.7] | NA | NA |
APL: advanced precancerous lesions [includes serrated lesions]; CRC: colorectal cancer; HGD: high-grade dysplasia; IBD-HGD/LGD: inflammatory bowel disease-associated dysplasia [high- or low-grade]; non-APL: non-advanced precancerous lesions; NA: not applicable.